Saba Capital Management Amends 13D Filing for abrdn Life Sciences
Ticker: HQL · Form: SC 13D/A · Filed: Apr 17, 2024 · CIK: 884121
| Field | Detail |
|---|---|
| Company | Abrdn Life Sciences Investors (HQL) |
| Form Type | SC 13D/A |
| Filed Date | Apr 17, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01, $34,175,076 |
| Sentiment | neutral |
Sentiment: neutral
Topics: activism, filing-amendment, shareholder-reporting
TL;DR
Saba Capital updated its 13D filing for abrdn Life Sciences Investors. Watch for potential moves.
AI Summary
Saba Capital Management, L.P. filed an amendment (No. 3) to its Schedule 13D on April 17, 2024, regarding its holdings in abrdn Life Sciences Investors. The filing indicates a change in the reporting person's beneficial ownership of the issuer's common shares.
Why It Matters
This amendment signals a potential shift in Saba Capital's stake or strategy concerning abrdn Life Sciences Investors, which could influence the company's stock performance.
Risk Assessment
Risk Level: medium — Changes in major shareholder filings can indicate shifts in investment strategy or potential activism, impacting stock price.
Key Players & Entities
- Saba Capital Management, L.P. (company) — Reporting Person
- abrdn Life Sciences Investors (company) — Issuer
- BOAZ R. WEINSTEIN (person) — Group Member
- SABA CAPITAL MANAGEMENT GP, LLC (company) — Group Member
FAQ
What specific changes were made in Amendment No. 3 to the Schedule 13D filing?
The filing is an amendment (No. 3) to the Schedule 13D, indicating a change in the reporting person's beneficial ownership of abrdn Life Sciences Investors' common shares.
Who is the reporting person in this filing?
The reporting person is Saba Capital Management, L.P.
What is the issuer's name and class of securities involved?
The issuer is abrdn Life Sciences Investors, and the class of securities is Common Shares, $0.01 par value.
When was this amendment filed with the SEC?
This amendment was filed on April 17, 2024.
What is the CUSIP number for the securities in question?
The CUSIP number is 87911K100.
Filing Stats: 1,342 words · 5 min read · ~4 pages · Grade level 10.8 · Accepted 2024-04-17 08:32:11
Key Financial Figures
- $0.01 — tors (Name of Issuer) Common Shares, $0.01 par value (Title of Class of Securiti
- $34,175,076 — ported herein. A total of approximately $34,175,076 was paid to acquire the Common Shares r
Filing Documents
- formsc13da.htm (SC 13D/A) — 63KB
- 0001062993-24-008455.txt ( ) — 65KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: April 17, 2024 SABA CAPITAL MANAGEMENT, L.P. By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Chief Compliance Officer SABA CAPITAL MANAGEMENT GP, LLC By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Authorized Signatory BOAZ R. WEINSTEIN By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Attorney-in-fact* * Pursuant to a power of attorney dated as of November 16, 2015, which is incorporated herein by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on December 28, 2015, accession number: 0001062993-15-006823 CUSIP No. 87911K100 SCHEDULE 13D/A Page 7 of 7 Pages Schedule A This Schedule sets forth information with respect to each purchase and sale of Common Shares which were effectuated by Saba Capital during the past sixty days. All transactions were effectuated in the open market through a broker. Trade Date Buy/Sell Shares Price 3/1/2024 Buy 382 13.69 3/4/2024 Buy 53,007 13.91 3/11/2024 Buy 1,102 13.74 3/12/2024 Buy 26,122 13.76 3/13/2024 Buy 32,492 13.82 3/14/2024 Buy 29,648 13.64 4/3/2024 Buy 3,037 13.22 4/4/2024 Buy 5,475 13.36 4/5/2024 Buy 5,811 13.12 4/8/2024 Buy 9,286 13.24 4/9/2024 Buy 423 13.25 4/10/2024 Buy 24,314 13.18 4/12/2024 Buy 22,041 13.04 4/15/2024 Buy 80,239 13.08